Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on November 26, 2024, the Compensation Committee of Senti Bio’s Board of Directors granted to three new employees stock options to purchase an aggregate of... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 16,713 shares of Series A... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnology and financial executive, to the Senti Bio Board of Directors (“Board”).... Read More

2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile Dose escalation is continuing with additional response and durability data expected in 2025 Conference call scheduled on December 3 at 7:30am ET SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. “Over the past quarter, we have continued... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor... Read More

Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc . (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (“CIRM”). Pursuant to the executed agreement with CIRM, the first... Read More

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a one-for-ten (1-for-10) reverse stock split of Senti Bio’s common stock, par value $0.0001 per share (the “Common... Read More

SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the California Institute for Regenerative Medicines (“CIRM”) has awarded an $8 million grant to Senti Bio. The CIRM grant will support the ongoing clinical development of... Read More

SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today... Read More

First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported... Read More

Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML Data supports the design of Phase 1 clinical trial of SENTI-202 with patient dosing anticipated in the second quarter of 2024 SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene... Read More

IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 Cash and anticipated receivables from GeneFab transaction expected to fund operations into the first quarter of 2025 SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a... Read More

Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 Anticipated cost savings, which includes an approximately 37% reduction in workforce, expected to extend cash runway into 1Q 2025 SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq:... Read More

First patient in Phase 1 clinical trial expected to be treated in Q2 2024 Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell therapy using Logic Gated Gene Circuits to selectively target cancer cells while sparing healthy bone marrow cells SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Senti... Read More

IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 Established new strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A to treat liver cancer in China Cash and receivables from GeneFab transaction expected to fund operations into Q4 2024 SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc.... Read More

Celest to lead clinical development with technical support from Senti Bio First patient expected to be enrolled in China in 1H 2024 Senti Bio eligible to receive up to $156 million in milestones and royalties SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene... Read More

Two poster presentations highlighting new preclinical data with BlueRock Therapeutics Two poster presentations showcasing Senti Bio’s proprietary Gene Circuit platform SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced four... Read More

Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies Abstracts include new preclinical data demonstrating ongoing progress from collaboration with BlueRock Therapeutics and new technology development to enable Senti's future oncology pipeline products SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences,... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor and healthcare industry conferences: Chardan's 7th Annual Genetic Medicines... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences: H.C. Wainwright 25th Annual Global Investment Conference Format:... Read More

GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on track for 2H 2023 Cash, cash equivalents, and short-term investments of $59.6 million as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company... Read More

Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies Transaction anticipated to extend Senti Bio’s cash runway into Q4 2024 Partnership with GeneFab will support manufacturing of Senti’s oncology programs, including SENTI-202, which remains on track for IND in 2H 2023 Dr. Philip Lee steps down as CTO of Senti... Read More

SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced multiple presentations highlighting the broad application of its Gene Circuit technologies in multiple modalities at the American Society of Gene and Cell Therapy (ASGCT)... Read More

New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform can work in T cells, AAVs, and iPSCs Cash, cash equivalents, and short-term investments of $76.1 million as of March 31,... Read More

Four abstracts accepted show the potential of applying gene circuits in multiple cell and gene therapy modalities for neurology, ophthalmology, and oncology New preclinical data demonstrate ongoing progress from collaborations with BlueRock and Spark SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and... Read More

Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission in 2H 2023 Additional data presented on SENTI-301A and crIL-15 support Senti’s development of gene circuit enhanced CAR-NK programs for multiple cancer indications SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a... Read More

SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences: Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Format: Fireside Chat Date: April 24,... Read More

SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS Preclinical data from multiple Gene Circuit enhanced CAR NK programs to be presented at American Association for Cancer Research (AACR) Annual Meeting in April 2023 Cash, cash equivalents, and short-term investments of $98.6 million as of... Read More

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced the acceptance of three abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Florida.... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that effective on February 1, 2023, the Compensation Committee of Senti Bio’s Board of Directors granted to 13 new employees stock options to purchase an aggregate... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, PhD, Senti’s Co-Founder and CEO, will present at the SVB Securities Global Biopharma Conference. Event details: SVB Securities Global Biopharma... Read More

R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors SENTI-202 on track for IND filing in 2H 2023 Cash runway guidance extended through at least Q1 2024 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that Tim Lu, MD, PhD, Co-founder and Chief Executive Officer, will present a corporate overview at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11,... Read More

– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic malignancies – – SENTI-202 is on track for IND filing in 2H 2023 – – SENTI-202 aims to more precisely target tumor cells in CD33 and/or FLT3 expressing tumors such as acute... Read More

Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML Live and webcast event on Sunday, December 11, 11:30 am - 12:30 pm CST SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and... Read More

SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33 and/or FLT3 expressing hematologic malignancies including MDS Selected development candidate for program to treat GPC3-expressing solid tumors including HCC, SENTI-301A; expected IND filing in 2023 Preclinical data from two solid tumor CAR-NK programs highlighted at SITC Cash position of $114.9 million as of September 30, 2022;... Read More

Senti Biosciences, Inc . (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit technology platform, today announced a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting, being held December 10-13, 2022, in New Orleans, LA. ASH presentation information: Date and Time: Saturday, December 10, 2022, 5:30 - 7:30... Read More

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on October 27, 2022, the compensation committee of Senti Bio’s board of directors granted to 9 new employees stock options to purchase an aggregate of 200,200 shares of the Company’s common stock with a per share exercise price of... Read More

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held November 10-12, 2022, in Boston, MA. Information about the poster sessions is as follows: Title: Multi-Arming and Regulator Dial... Read More

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman, and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Chardan’s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, at 1:30 PM ET. Tim Lu will also... Read More

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 4:05 p.m. ET. A live... Read More

Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution used to support the unique needs of its clients. The ChEF enables companies to raise equity on a periodic basis after becoming public, outside the context of a traditional underwritten follow-on offering. Companies that have recently announced ChEFs include Senti Biosciences, Inc.... Read More

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on August 18, 2022, the compensation committee of Senti Bio’s board of directors granted to thirty five new employees stock options to purchase an aggregate of 421,659 shares of the Company’s common stock with a per share exercise... Read More

Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 Cash position of $139.8 million as of June 30, 2022 expected to fund current operating plan into 2024 Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its... Read More